Gyre Therapeutics, Inc. - Common Stock (NQ:GYRE)

6.325 +0.135 (+2.18%)

Streaming Delayed Price Updated: 12:43 PM EDT, Jun 5, 2026 Add to My Watchlist

Price and Volume

Volume	71,351
Open	6.200
Bid (Size)	6.300 (1,200)
Ask (Size)	6.350 (200)
Prev. Close	6.190
Today's Range	6.128 - 6.660
52wk Range	5.440 - 9.420
Shares Outstanding	37,759,825
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

May 12, 2026

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update

May 07, 2026

From Gyre Therapeutics Inc.

Via GlobeNewswire

Performance

YTD	-7.1%	-7.1%
1 Month	-18.7%	-18.7%
3 Month	-19.2%	-19.2%
6 Month	-19.9%	-19.9%
1 Year	-26.3%	-26.3%

More News

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company

May 04, 2026

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

March 17, 2026

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 12, 2026

From Gyre Therapeutics Inc.

Via GlobeNewswire

Pulmatrix Shares Dive As Privately-Held Pharma Company Chooses To Merge With Gyre Therapeutics Instead ↗

March 02, 2026

Via Stocktwits

Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

January 05, 2026

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Inc (NASDAQ:GYRE) Reports Q3 2025 Earnings Beat Amid Revenue Miss and Lowered Guidance ↗

November 07, 2025

Via Chartmill

Earnings Scheduled For November 7, 2025 ↗

November 07, 2025

Via Benzinga

Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update

November 07, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

October 15, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

October 14, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 10, 2025

Via Benzinga

Elastic, Applied Digital, Eightco Holdings And Other Big Stocks Moving Higher On Friday ↗

October 10, 2025

Via Benzinga

This Aptiv Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

October 10, 2025

Via Benzinga

BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone

September 09, 2025

Via Investor Brand Network

Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

September 05, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker ↗

August 26, 2025

Via Benzinga

This Actuate Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗

August 26, 2025

Via Benzinga

Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors

August 22, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update

August 11, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China

June 10, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

May 29, 2025

From Gyre Therapeutics Inc.

Via GlobeNewswire

MAC Copper, ATS, Pony AI And Other Big Stocks Moving Higher On Tuesday ↗

May 27, 2025

Via Benzinga

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

May 23, 2025

Via Chartmill

Frequently Asked Questions

Is Gyre Therapeutics, Inc. - Common Stock publicly traded?

Yes, Gyre Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Gyre Therapeutics, Inc. - Common Stock trade on?

Gyre Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Gyre Therapeutics, Inc. - Common Stock?

The ticker symbol for Gyre Therapeutics, Inc. - Common Stock is GYRE on the Nasdaq Stock Market

What is the current price of Gyre Therapeutics, Inc. - Common Stock?

The current price of Gyre Therapeutics, Inc. - Common Stock is 6.325

When was Gyre Therapeutics, Inc. - Common Stock last traded?

The last trade of Gyre Therapeutics, Inc. - Common Stock was at 06/05/26 12:43 PM ET

What is the market capitalization of Gyre Therapeutics, Inc. - Common Stock?

The market capitalization of Gyre Therapeutics, Inc. - Common Stock is 238.83M

How many shares of Gyre Therapeutics, Inc. - Common Stock are outstanding?

Gyre Therapeutics, Inc. - Common Stock has 239M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.